Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03284632 · ClinicalTrials.gov registry record
e-Cigarette - DNA Adducts
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 217
- Enrollment target
NCT03284632: Completed study, sponsored by University of Minnesota.
NCT03284632 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 217 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03284632 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 217 participants
- Enrollment target
Study Summary
This study will examine the level of toxicity of e-cigarette use compared to smokers and nonsmokers including inflammation markers, toxicant and carcinogen exposure. Additionally, the study will look at the effect of varying voltage levels for e-cigarette users.
Primary Outcome
Formation of Formaldehyde DNA Adducts in oral cells before and after smoking or vaping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2017-07-11 |
| Est. Completion | 2021-06-01 |
What the finished NCT03284632 record still lists
NCT03284632 is an observational study that tracks outcomes without assigning an intervention. The registered 217 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03284632 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03284632 about?
NCT03284632 is a clinical study titled "e-Cigarette - DNA Adducts". This study will examine the level of toxicity of e-cigarette use compared to smokers and nonsmokers including inflammation markers, toxicant and carcinogen exposure. Additionally, the study will look at the effect of varying voltage levels for e-cigarette users.
What is the current status of trial NCT03284632?
This trial is currently completed. The enrollment target is 217 participants. The study started on 2017-07-11. Estimated completion is 2021-06-01.
Who is sponsoring clinical trial NCT03284632?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079282 · 217 participants · Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- NCT05470439 · 217 participants · NA
My Interprofessional Care Team for Adherence and Research Engagement Disparities
- NCT05981703 · 217 participants · Phase 1
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- NCT06342258 · 217 participants · Phase 1
COES: Curing Order Effects on Sealants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI